Sun Pharma gets FDA approval for diabetes generic drug

Fri Jul 12, 2013 8:40am IST

Related Topics

Stocks

   

REUTERS - Sun Pharmaceutical Industries(SUN.NS) said on Friday it has received final approval from the United States Food and Drug Administration (FDA) to launch the generic version of Novo Nordisk's (NOVOb.CO) Prandin diabetes drug.

Prandin, known chemically as repaglinide, and its combination with the commonly prescribed type 2 diabetes drug metformin, sold as PrandiMet, had sales of about $200 million in 2012 for Novo.

Sun Pharma said it would be eligible for a 180-day marketing exclusivity in the United States for the drug.

A U.S. appeals court last month found the patent on Novo's Prandin diabetes drug in combination with metformin to be invalid, paving the way for the introduction of a generic version of the drug.

(Reporting by Sumeet Chatterjee in MUMBAI; Editing by Supriya Kurane)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Iron Ore Mining

REUTERS SHOWCASE

Telecom Sector

Telecom Sector

RIL telecoms unit in tower lease pact with ATC  Full Article 

Japanese Economy

Japanese Economy

Japan exports growth slows sharply, keeps pressure on BOJ to act  Full Article 

A Tough Sell

A Tough Sell

Insurance against a China financial crisis  Full Article 

Tyre Debris

Tyre Debris

Bangalore-bound Malaysia Airlines plane turns back after tyre burst on takeoff  Full Article 

Digital Currency

Digital Currency

At Mt. Gox bitcoin hub, 'geek' CEO sought both control and escape  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage